Inhibikase Therapeutics Statistics
NASDAQ: IKTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
1.32+0.02 (+1.54%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Inhibikase Therapeutics by the numbers
Inhibikase Therapeutics has a market capitalization of $185.2 million based on 140.27M shares outstanding. With trailing EPS of $-0.40, Inhibikase Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 26.3% below its 50-day average and 31.4% below its 200-day average.
Average daily trading volume is 584.27K shares, or about $771,238 in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
IKT valuation vs. peer median
| Metric | IKT | Peer median | Difference |
|---|---|---|---|
| Market cap | $185.16M | $191.06M | -3% |
| Avg. volume | 584.27K | 1.22M | -52% |
Peer median across 8 companies: ARTV, CGEN, LCTX, CABA, IPSC, PALI, ALLO, STRO.
Valuation
- Market cap
- $185.16M
- EPS (TTM)
- $-0.40
- Shares outstanding
- 140.27M
Price and trading
- Previous close
- 1.30
- Open
- 1.28
- Day range
- 1.28 – 1.37
- 52-week range
- 1.28 – 2.61
- 52-week change
- -11.41%
- Beta
- —
- Volume
- 1.11M
- Average volume
- 584.27K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 10, 2026
Additional statistics
- Market Cap
- 185.16M
- Forward Pe
- -3.32
- Eps
- -0.40
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 2.61
- Week52 Low
- 1.28
- Avg Volume
- 584.27K
- Shares Outstanding
- 140.27M
- Ma50
- 1.79
- Ma200
- 1.93
- Earnings Date
- Nov 10, 2026
- Pct From52w High
- -49.43%
- Pct From52w Low
- 3.13%